Skip to content
lifestyle.womensconference.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cingulate Inc.
Cingulate Receives Complete Response Letter from FDA for CTx-1301
June 2, 2026
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
May 24, 2026
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
March 18, 2026
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
February 17, 2026